Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492566 | 1.00 | CYP2C19 (0.47) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624124 | 0.93 | CYP2C19 (0.43) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624107 | 0.93 | CYP2C19 (0.43) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624154 | 0.93 | CYP2C19 (0.43) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624130 | 0.92 | CYP2C19 (0.44) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624140 | 0.92 | CYP2C19 (0.44) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL15624150 | 0.91 | CYP2C19 (0.45) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5490064 | 0.84 | CYP2C19 (0.45) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5490071 | 0.84 | CYP2C19 (0.45) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5490069 | 0.83 | FKBP4 (0.50) | CYP2C19MAPTCYP2D6CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | claimed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | claimed |
| EP-1458680-A1 | PRODRUGS TO D-PROLINES | F. Hoffmann-La Roche AG (CH) | 2004-09-22 | — | — | EP | claimed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | claimed |
| WO-2003051836-A1 | PRODRUGS TO D-PROLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | claimed |
| US-20030060543-A1 | Polyolefin additive packages for producing articles with enhanced stain resistance | BRASKEM AMERICA, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002096985-A1 | POLYOLEFIN ADDITIVE PACKAGES FOR PRODUCING ARTICLES WITH ENHANCED STAIN RESISTANCE | SUNOCO, INC. (R & M) (US) | 2002-12-05 | — | — | WO | claimed |
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1458680-A1 | PRODRUGS TO D-PROLINES | F. Hoffmann-La Roche AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-6777470-B2 | AT LEAST ONE NON-PHENOLIC ANTIOXIDANT AND A HINDERED AMINE LIGHT STABILIZER. | SUNOCO, INC. (R&M) | 2004-08-17 | — | — | US | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
| WO-2003051836-A1 | PRODRUGS TO D-PROLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
| US-20030060543-A1 | Polyolefin additive packages for producing articles with enhanced stain resistance | BRASKEM AMERICA, INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | CYP2C19 1676/4885MAPT 1923/4885CYP2D6 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.